PR93049

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

TEL AVIV, Israel and RALEIGH, N.C., Nov. 15, 2021 /PRNewswire=KYODO JBN/ --

- Recruitment completed for Part A of the Phase 2/3 study of once-daily

orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19

who do not require hospital care

- Top-line results for Part A of the study, designed to evaluate safety and

tolerability of RHB-107 and dose selection, expected in Q1/ 22

- RHB-107 is a novel, investigational antiviral serine protease inhibitor

targeting human cell factors and is expected to be effective against emerging

viral variants

- In parallel, data packages for opaganib, RedHill's other advanced novel oral

COVID-19 drug candidate, have been submitted in the U.S., EU, UK and other

territories, ahead of planned regulatory advice

RedHill Biopharma Ltd. [https://www.redhillbio.com/home/default.aspx] (Nasdaq:

RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company,

today announced that the last patient has been enrolled in Part A of the Phase

2/3 study with novel, once-daily, orally-administered pill RHB-107

(upamostat)[1] for non-hospitalized patients with symptomatic COVID-19. The

study is being conducted in the U.S. and South Africa.

The Phase 2/3 study (NCT04723527

[https://clinicaltrials.gov/ct2/show/NCT04723537?term=RHB-107&draw=2&rank=1])

with RHB-107 is aimed at evaluating treatment in patients with symptomatic

COVID-19 early in the course of the disease, with a once-daily oral treatment

that can be prescribed and used in the non-hospitalized patient population. The

study is a 2-part, multicenter, randomized, double-blind, placebo-controlled,

parallel-group study to evaluate the safety and efficacy of RHB-107. The study

is designed to evaluate time to sustained recovery from illness as the primary

endpoint and for dose selection. A total of 61 patients have been enrolled in

Part A and randomized on a 1:1:1 basis to receive one of two doses of upamostat

or placebo. Based on safety and tolerability results of part A, a dose for part

B will be selected, and patients will be randomized 3:2 to active vs. placebo.

Patients are also tested for specific viral strain. Top-line results from Part

A of the study are expected in the first quarter of 2022, with Part B of the

study expected to follow subsequent to discussions with regulators.

"Once again, we see a rise in COVID-19 infections in many countries across the

world – and the need for effective, simple and safe oral therapies that can be

used outside the hospital setting, and that can work across COVID-19 variants,

is significant," said Terry F. Plasse MD, Medical Director at RedHill.

"Completing randomization for Part A of the RHB-107 Phase 2/3 study is an

important step forward for this elegant, once-daily novel oral pill as a

potential treatment of COVID-19 in the community."

RHB-107 is a novel antiviral drug candidate that targets human serine proteases

involved in preparing the spike protein for viral entry into target cells.

Because it is host-cell targeted, RHB-107 is expected to also be effective

against emerging viral variants with mutations in the spike protein. RHB-107

has demonstrated strong inhibition of SARS-CoV-2 viral replication in an in

vitro human bronchial epithelial cell model. RHB-107 has a strong clinical

safety and biodistribution profile, demonstrated in previous clinical studies,

including several Phase 1 and Phase 2 studies in different indications, in

approximately 200 patients.

In parallel, data packages for opaganib[2], RedHill's other advanced novel oral

COVID-19 drug candidate – have been submitted to regulators in various

territories including the U.S., EU, UK and others, ahead of planned regulatory

advice. Opaganib's global Phase 2/3 study in patients hospitalized with severe

COVID-19 demonstrated a 62% reduction in mortality as well as improved outcomes

in time to room air and median time to hospital discharge in a sub-group of 251

moderately severe patients, comprising 54% of the study participants.

About RHB-107 (upamostat)

RHB-107 is a proprietary, first-in-class, orally-administered antiviral, that

targets human serine proteases involved in preparing the spike protein for

viral entry into target cells. RHB-107 targets human cell factors involved in

preparing the spike protein for viral entry into target cells and is therefore

expected to be effective against emerging viral variants with mutations in the

spike protein. RHB-107 is being evaluated in a Phase 2/3 study for treatment of

patients with symptomatic COVID-19 who do not require inpatient care. In

addition, RHB-107 inhibits several proteases targeting cancer and inflammatory

gastrointestinal disease. RHB-107 has undergone several Phase 1 studies and two

Phase 2 studies, demonstrating its clinical safety profile in approximately 200

patients. RedHill acquired the exclusive worldwide rights to RHB-107, excluding

China, Hong Kong, Taiwan and Macao, from Germany's Heidelberg Pharmaceuticals

(FSE: HPHA) (formerly WILEX AG) for all indications.

About RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company

primarily focused on gastrointestinal and infectious diseases. RedHill promotes

the gastrointestinal drugs, Movantik® for opioid-induced constipation in

adults[3], Talicia® for the treatment of Helicobacter pylori (H. pylori)

infection in adults[4], and Aemcolo® for the treatment of travelers' diarrhea

in adults[5]. RedHill's key clinical late-stage development programs include:

(i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous

mycobacteria (NTM) disease; (ii) opaganib ( ABC294640), a first-in-class, oral

SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program

for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma

ongoing; (iii) RHB-107 (upamostat), an oral serine protease inhibitor in a U.S.

Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple

other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with

positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102,

with positive results from a Phase 3 study for acute gastroenteritis and

gastritis and positive results from a Phase 2 study for IBS-D; and (vi)

RHB-106, an encapsulated bowel preparation. More information about the Company

is available at www.redhillbio.com / https://twitter.com/RedHillBio.

This press release contains "forward-looking statements" within the meaning of

the Private Securities Litigation Reform Act of 1995. Such statements may be

preceded by the words "intends," "may," "will," "plans," "expects,"

"anticipates," "projects," "predicts," "estimates," "aims," "believes,"

"hopes," "potential" or similar words. Forward-looking statements are based on

certain assumptions and are subject to various known and unknown risks and

uncertainties, many of which are beyond the Company's control and cannot be

predicted or quantified, and consequently, actual results may differ materially

from those expressed or implied by such forward-looking statements. Such risks

and uncertainties include, without limitation, the risk that the follow up for

Part A and the commencement of Part B of the Phase 2/3 study evaluating RHB-107

in patients with symptomatic COVID-19 will be delayed, not completed or not

successful; the risk that RHB-107 and/or opaganib will not be effective against

emerging viral variants with mutations in the spike protein; the risk that the

Company's Phase 2/3 development program evaluating RHB-107 and/or opaganib will

not be successful and that the data from this clinical study will be delayed,

if at all; the risk of a delay in receiving data to support emergency use

applications or in making such emergency use applications, if at all; the risk

that the Company will not initiate the Phase 2/3 study for RHB-107 in certain

geographies, including South Africa, will not expand this study to additional

sites in the U.S. and that it will not be successful and that enrollment will

be delayed; the risk that COVID-19 patients treated with RHB-107 or opaganib

will not show any clinical improvement; the development risks of early-stage

discovery efforts for a relatively new disease, including difficulty in

assessing the efficacy of RHB-107 and opaganib for the treatment of COVID-19,

if at all; intense competition from other companies developing potential

treatments and vaccines for COVID-19; the effect of a potential occurrence of

patients suffering serious adverse events using RHB-107, as well as risks and

uncertainties associated with (i) the initiation, timing, progress and results

of the Company's research, manufacturing, preclinical studies, clinical trials,

and other therapeutic candidate development efforts, and the timing of the

commercial launch of its commercial products and ones it may acquire or develop

in the future; (ii) the Company's ability to advance its therapeutic candidates

into clinical trials or to successfully complete its preclinical studies or

clinical trials (iii) the extent and number and type of additional studies that

the Company may be required to conduct and the Company's receipt of regulatory

approvals for its therapeutic candidates, and the timing of other regulatory

filings, approvals and feedback; (iv) the manufacturing, clinical development,

commercialization, and market acceptance of the Company's therapeutic

candidates and Talicia®; (v) the Company's ability to successfully

commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company's

ability to establish and maintain corporate collaborations; (vii) the Company's

ability to acquire products approved for marketing in the U.S. that achieve

commercial success and build and sustain its own marketing and

commercialization capabilities; (viii) the interpretation of the properties and

characteristics of the Company's therapeutic candidates and the results

obtained with its therapeutic candidates in research, preclinical studies or

clinical trials; (ix) the implementation of the Company's business model,

strategic plans for its business and therapeutic candidates; (x) the scope of

protection the Company is able to establish and maintain for intellectual

property rights covering its therapeutic candidates and commercial products and

its ability to operate its business without infringing the intellectual

property rights of others; (xi) parties from whom the Company licenses its

intellectual property defaulting in their obligations to the Company; (xii)

estimates of the Company's expenses, future revenues, capital requirements and

needs for additional financing; (xiii) the effect of patients suffering adverse

events using investigative drugs under the Company's Expanded Access Program;

and (xiv) competition from other companies and technologies within the

Company's industry. More detailed information about the Company and the risk

factors that may affect the realization of forward-looking statements is set

forth in the Company's filings with the Securities and Exchange Commission

(SEC), including the Company's Annual Report on Form 20-F filed with the SEC on

March 18, 2021. All forward-looking statements included in this press release

are made only as of the date of this press release. The Company assumes no

obligation to update any written or oral forward-looking statement, whether as

a result of new information, future events or otherwise unless required by law.

Category: R&D

1. RHB-107 (upamostat) is an investigational new drug, not available for

commercial distribution in the United States.

2. Opaganib is an investigational new drug, not available for commercial

distribution in the United States.

3. Full prescribing information for Movantik® (naloxegol) is available at:

www.Movantik.com.

4. Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin

and rifabutin) is available at: www.Talicia.com.

5. Full prescribing information for Aemcolo® (rifamycin) is available at:

www.Aemcolo.com.

Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com

UK: Amber Fennell, Consilium

+44 (0)7739 658 783

fennell@consilium-comms.com

Source: RedHill Biopharma Ltd.